TBNTechPolitics
The DEA banned a drug some opioid users called a miracle
Publication: Ars Technica - All content
Author: Manisha Krishnan, wired.com
Source published: 04/11/2026, 15:08:48 UTC
Briefing created: 04/11/2026, 18:54:21 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 04/11/2026, 16:28:24 UTC.
Briefings
In 2017, Laura Bohn and her team at the University of South Florida Health, funded by the National Institute on Drug Abuse, published findings in the journal Cell identifying SR-17018 as a potential pain reliever for mice. The study revealed that SR-17018 could manage pain without causing respiratory depression, a critical safety advantage over opioids. The researchers discovered the compound did not induce high tolerance in mice and allowed dependent mice to reset their tolerance without withdrawal pain. This research was a pivotal step in the search for safer alternatives to opioids.
Key points
- Laura Bohn and her team at the University of South Florida Health published findings in the journal Cell in 2017 identifying SR-17018 as a pain reliever for mice without respiratory depression.
- The compound did not induce high tolerance in mice and allowed dependent mice to reset their tolerance without withdrawal pain.
Context
This research represents a significant advancement in pain management research, specifically addressing the safety concerns associated with opioid use. The study was funded by the National Institute on Drug Abuse and aimed to identify safer alternatives to opioids.
Limitations
The evidence is limited to a 2017 study published in the journal Cell involving mice. The study does not include human clinical trials, and the specific efficacy of SR-17018 in humans remains unverified. The findings are observational and do not constitute a direct recommendation for clinical use.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 04/11/2026, 18:54:21 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeid276xogwxxwyltbbhpqsbqsnk6dxbqhkjqzl6utuhv7uddmtd6lu